(IN BRIEF) Novartis has reported positive interim results from its Phase III ALIGN study involving atrasentan, an oral endothelin A receptor antagonist, for the treatment of IgA nephropathy (IgAN). The study demonstrated that atrasentan significantly reduced proteinuria (excess protein in … Read the full press release
(IN BRIEF) ViiV Healthcare has received approval from China’s National Medical Products Administration (NMPA) for Vocabria (cabotegravir) in combination with Rekambys (rilpivirine), marking the first complete long-acting HIV-1 injectable treatment in China. This approval allows people living with HIV in … Read the full press release
Posted in Business, Environment, Financial, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged cabotegravir, CHINA, Chinese Approval, Deborah Waterhouse, GSK, HIV, injection, partnership, Pfizer, Rekambys, rilpivirine, Shionogi, sustainability, treatment, ViiV Healthcare, Vocabria
(IN BRIEF) Pfizer and BioNTech have announced positive topline results from a Phase 1/2 study of their mRNA-based combination vaccine program for influenza and COVID-19. The lead formulations showed robust immune responses to influenza A, influenza B, and SARS-CoV-2 strains. … Read the full press release
Posted in Business, Environment, Financial, Germany, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged Annaliesa Anderson, BioNTech, Combination Vaccine, Comirnaty, COVID-19, influenza, influenza A, influenza B, mRNA, partnership, Pfizer, Prof. Ugur Sahin, respiratory diseases, SARS-CoV-2 strains, sustainability, wellness
(IN BRIEF) AstraZeneca’s Supplemental Biologics License Application (sBLA) seeking approval for a self- or caregiver-administered option for FluMist Quadrivalent, a needle-free nasal spray flu vaccine, has been accepted for review by the US Food and Drug Administration (FDA). If approved, … Read the full press release
(IN BRIEF) Evonik’s life sciences division, Nutrition & Care, has introduced GMP (Good Manufacturing Practices) production of PhytoSquene®, a non-animal-derived squalene derived from amaranth oil. PhytoSquene® offers a sustainable alternative to squalene sourced from shark liver oil and is intended … Read the full press release
Posted in Business, Chemicals, Germany, Healthcare, Industrial, Management, News, Pharma & Biotech, Science
Tagged Evonik, GMP Production, Paul Spencer, Pharmaceutical Use, PhytoSquene®, Plant-Based Squalene
(IN BRIEF) BioNTech SE is set to reveal its financial results for the third quarter of 2023 on November 6th, 2023. The company invites investors and the public to participate in a conference call and webcast at 8:00 a.m. ET … Read the full press release
Posted in Business, Financial, Germany, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged BioNTech, Financial, INNOVATION, investment
(IN BRIEF) AstraZeneca and Daiichi Sankyo have received European Union (EU) approval for their drug Enhertu as a monotherapy for the treatment of advanced non-small cell lung cancer (NSCLC) in adult patients with activating HER2 mutations who require systemic therapy … Read the full press release
Posted in Business, Environment, European Union, Healthcare, Industrial, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged AstraZeneca, Daiichi Sankyo, Dave Fredrickson, Enhertu, EU approval, HER2-Mutant, Ken Keller, lung cancer, Martin Reck, monotherapy, NSCLC, partnership, sustainability
(IN BRIEF) ViiV Healthcare, a global specialist HIV company, will present 23 abstracts at the 19th Annual European AIDS Conference (EACS 2023). These abstracts will cover various aspects of HIV treatment and prevention, including real-world data on long-acting and 2-drug … Read the full press release
Posted in Business, Education, Financial, Healthcare, Industrial, Investment, Management, Media, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Apretude, Dovato, EACS 2023, GSK, HIV, Kimberly Smith, partnership, Pfizer, prevention, Rekambys, Rukobia, Shionogi, treatment, ViiV Healthcare, Vocabria
(IN BRIEF) Soliris (eculizumab) has received approval in China for the treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody positive (Ab+). This makes Soliris the first and only complement inhibitor approved for NMOSD … Read the full press release
(IN BRIEF) Merck, a leading science and technology company, has announced its expectation to return to organic sales growth in fiscal 2024. This was revealed during the company’s Capital Markets Day. Despite challenging market conditions in its Life Science and … Read the full press release
Posted in Artificial Intelligence (AI), Business, Electronics & Machinery, Financial, Germany, Healthcare, Management, Pharma & Biotech, Technology
Tagged artificial-intelligence, BAVENCIO™, Belén Garijo, Capital Markets Day, electronics, evobrutini, Healthcare, Internet of Things, IoT, Life Science, MAVENCLAD, Merck, semiconductor materials, Xevinapant
(IN BRIEF) Servier, a global pharmaceutical group, has partnered with Owkin, a biotech company specializing in AI-driven drug discovery and diagnostics, to accelerate the development of better-targeted therapies in various disease areas, including oncology. The collaboration aims to leverage AI … Read the full press release
Posted in Artificial Intelligence (AI), Business, Education, Environment, Financial, France, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged AI, Claude Bertrand, Disease Treatment, INNOVATION, oncology, Owkin, partnership, Servier, sustainability, therapies, Thomas Clozel
(IN BRIEF) Merck, a leading science and technology company, is set to present 28 abstracts at the 2023 European Society of Medical Oncology (ESMO) Annual Meeting in Madrid. These abstracts will showcase the latest research on Merck’s oncology portfolio, addressing … Read the full press release
Posted in Business, Germany, Healthcare, Management, Media, News, Pharma & Biotech, Science, Spain, Technology
Tagged BAVENCIO™, bladder, cancer treatment, colorectal, ERBITUX, ESMO 2023, head and neck, lung, Madrid, Merck, oncology, TEPMETKO, Xevinapant
(IN BRIEF) BioNTech will be presenting updates on multiple programs across its oncology pipeline at the European Society for Molecular Oncology (ESMO) Congress 2023. These updates include data on investigational CAR-T and ex-vivo T cell therapies, a novel ADC (antibody-drug … Read the full press release
Posted in Business, Education, Germany, Healthcare, Industrial, Management, Media, News, Pharma & Biotech, Science, Technology
Tagged BioNTech, BNT211, BNT325, cancer therapy, CAR-T, ESMO Congress 2023, ex-vivo T cell therapies, Prof. Özlem Türeci
(IN BRIEF) AstraZeneca’s supplemental New Drug Application (sNDA) for Tagrisso (osimertinib) in combination with chemotherapy has been granted Priority Review by the US Food and Drug Administration (FDA) for the treatment of adult patients with locally advanced or metastatic epidermal … Read the full press release
Posted in Business, Education, Healthcare, Industrial, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged AstraZeneca, chemotherapy, EGFR, FLAURA2, lung cancer, osimertinib, Susan Galbraith, Tagrisso, Treatment USA
(IN BRIEF) GSK has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for the approval of Jemperli (dostarlimab) in combination with chemotherapy as a frontline treatment for adult … Read the full press release
Posted in Business, Education, Healthcare, Industrial, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged chemotherapy, CHMP, dostarlimab, endometrial cancer, GSK, Hesham Abdullah, Jemperli, RUBY, treatment
(IN BRIEF) EpimAb Biotherapeutics, a clinical-stage biopharmaceutical company specializing in multispecific antibodies, and Almirall, a global biopharmaceutical company focused on medical dermatology, have entered into a license agreement to develop bispecific antibodies for up to three undisclosed target pairs. Almirall … Read the full press release
Posted in Business, Environment, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Spain, Technology
Tagged Almirall, antibodies, Dr. Chengbin Wu, EpimAb, Fabs-In-Tandem Immunoglobulin (FIT-Ig®), Karl Ziegelbauer, Multiple Targets, partnership, sustainability
(IN BRIEF) QIAGEN is organizing the Global TB Clinical and Educational Summit 2023, running from October 17-19, with the theme “Tackling TB together: From awareness to action.” This summit highlights QIAGEN’s dedication to combat tuberculosis (TB) and address the gap … Read the full press release
(IN BRIEF) AstraZeneca has revealed the eight winners of its 2023 R&D Postdoctoral Challenge, an initiative that supports early-career scientists in pursuing their innovative research proposals. Unlike traditional industry postdoctoral programs, this unique challenge allows researchers from around the world … Read the full press release
(IN BRIEF) AstraZeneca is set to present new data at the 12th annual IDWeek conference, emphasizing the role of long-acting antibodies and vaccines in safeguarding at-risk individuals from common infectious respiratory diseases. The company will share 15 abstracts, including oral … Read the full press release
(IN BRIEF) Alexion, a subsidiary of AstraZeneca Rare Disease, is set to present new data at the 9th Joint Meeting of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple … Read the full press release
Posted in Business, Education, Healthcare, Industrial, Management, Media, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Alexion, Alize Vives, Anna Francis, AQP4, AstraZeneca, Christophe Hotermans, ECTRIMS-ACTRIMS Meeting, effectiveness, Jin Nakahara, Justin Lee, Michael Levy, multiple sclerosis, NMOSD, Rare Neurological Disorder, rituximab, Sami Fam, Soliris, treatment, Ultomiris, Viktoria Papp
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?